Recent Updates
Recently added Catalysts
GKOS Positive Sentiment

Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases

Thursday, October 8, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Glaukos Corporation has entered into an exclusive license agreement with RevOpsis Therapeutics to develop and commercialize RO-104, a novel tri-specific biologic. This biologic aims to treat retinal diseases, specifically targeting neovascular age-related macular degeneration and diabetic macula edema. The partnership highlights Glaukos's commitment to advancing innovative therapies in ophthalmology.

Market Sentiment Analysis

POSITIVE FACTORS

  • Exclusive license agreement with RevOpsis Therapeutics.
  • Development of a first-in-class tri-specific biologic.
  • Targeting significant retinal diseases like nAMD and DME.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+66%
120-day peak, hindsight
Typical move
8.7%
average across 4 past catalysts
Lead asset
Test Article A
Phase 3 · Progressive Keratoconus

Full Press Release Details

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced an exclusive license agreement with RevOpsis Therapeutics, Inc. to develop and commercialize RO-104, a novel tri-specific biologic for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macula edema (DME), diabetic retinopat

Frequently Asked Questions

What is RO-104?

RO-104 is a first-in-class tri-specific biologic developed for retinal diseases.

What diseases does RO-104 target?

It targets neovascular age-related macular degeneration and diabetic macula edema.

Who is partnering with Glaukos?

Glaukos has partnered with RevOpsis Therapeutics for this development.

What type of agreement was announced?

An exclusive license agreement was announced between Glaukos and RevOpsis.

ShareAdd on Google
Tags: GKOS Glaukos RevOpsis Therapeutics retinal diseases tri-specific biologic nAMD
Last updated: Oct 8, 2026

Biotech snapshot

Cash runway
$286M liquidity · $0M/mo burn
Low dilution risk
Lead asset
Test Article APhase 3
Progressive Keratoconus →

Catalyst track record

+66%
best trade around GKOS's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for GKOS.

See every catalyst's timing & PoA →